METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS

NIH RePORTER · NIH · R01 · $813,454 · view on reporter.nih.gov ↗

Abstract

This proposal will test the hypothesis that host-derived aldehydes are a critical component of host immunity against Mycobacterium tuberculosis. We will use bacterial and mouse genetics, biochemistry, immunology and cell biology experiments to test this hypothesis. We will identify bacterial mutants that are either more resistant or more sensitive than parental strains to various aldehydes in combination with nitric oxide, which appears to strongly synergize with several different aldehydes to kill bacteria. The isolation of these bacterial strains will allow us to test whether or not these pathways contribute to bacterial survival in mice. We will also investigate various host pathways from aerobic glycolysis to aldehyde dehydrogenase activity to assess the contribution of aldehyde products of these pathways in bacterial infection control. The outcome of our studies may ultimately help promote a clinical trial repurposing an FDA-approved drug for the treatment of tuberculosis and possibly other diseases.

Key facts

NIH application ID
10172843
Project number
5R01AI153197-02
Recipient
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Principal Investigator
Katerina Heran Darwin
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$813,454
Award type
5
Project period
2020-06-01 → 2025-05-31